Inhibrx Biosciences, Inc.
General ticker "INBX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $715.1M (TTM average)
Inhibrx Biosciences, Inc. follows the US Stock Market performance with the rate: 59.3%.
Estimated limits based on current volatility of 3.4%: low 93.70$, high 100.23$
Factors to consider:
- Total employees count: 1000000 (+581295.3%) as of 2024
- Top business risk factors: Economic downturns and volatility, Intellectual property risks, Product liability, Labor/talent shortage/retention, Cybersecurity threats
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [33.44$, 88.77$]
- 2026-12-31 to 2027-12-31 estimated range: [20.48$, 56.68$]
Financial Metrics affecting the INBX estimates:
- Negative: with PPE of -9.0 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 5.46 <= 19.24
- Negative: 0.73 < Interest expense per share per price, % of 0.96
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -13.66 <= 0
Short-term INBX quotes
Long-term INBX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.80MM | $0.20MM | $1.30MM |
| Operating Expenses | $221.02MM | $331.65MM | $136.32MM |
| Operating Income | $-219.22MM | $-331.45MM | $-135.03MM |
| Non-Operating Income | $-20.50MM | $2,019.02MM | $-5.03MM |
| Interest Expense | $31.84MM | $13.49MM | $12.20MM |
| R&D Expense | $191.64MM | $203.74MM | $113.03MM |
| Income(Loss) | $-239.72MM | $1,687.57MM | $-140.05MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Other Income(Loss) | $-1.63MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-243.00MM | $1,687.57MM | $-140.06MM |
| Stockholders Equity | $43.50MM | $133.58MM | $7.99MM |
| Assets | $307.89MM | $180.77MM | $146.48MM |
| Operating Cash Flow | $-193.31MM | $-194.41MM | $-129.79MM |
| Capital expenditure | $4.59MM | $2.60MM | $0.03MM |
| Investing Cash Flow | $-4.59MM | $-2.60MM | $-0.03MM |
| Financing Cash Flow | $201.96MM | $71.68MM | $101.45MM |
| Earnings Per Share** | $-5.16 | $116.58 | $-9.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.